DexCom New Projects ATTRACT Attention Among Analyst Action Friday

Google Inc. (NASDAQ:GOOG): As a result of macro uncertainty and currency weakness, Citigroup has reduced its Google estimates to below consensus, and the firm decreased its price target for shares from $750 to $740. On the other hand, Citi does see Google shares as attractive and maintains a Buy rating on the shares.

Investing Insights: Why is China ATTACKING Baidu and Google?

Great Plains Energy Incorporated (NYSE:GXP) guidance range for 2012 will remain intact, Citigroup predicts following a meeting with management. The firm does not think that management will decrease its EPS outlook for 2012 even though Q1 showed milder than average weather. Citi maintains a Buy rating and a $23 price target on the stock.

Rovi Corporation (NASDAQ:ROVI) has had its estimates reduced by Piper Jaffray as a reflection of lowered expectations in regards to the Rovi Entertainment Store. Piper believes the valuation at current levels is attractive, and the firm maintains an Overweight rating and a $35 price target on the stock.

DexCom, Inc. (NASDAQ:DXCM): Following a meeting with management in regards to the regulatory status of the Gen4 sensor, partner projects, as well as new product pipelines, Canaccord has increased DexCom’s price target. The firm gives a Buy rating on shares.

Celgene Corporation (NASDAQ:CELG): According to William Blair, Celgene is the most attractive  large-cap biotech stock after the sell-off yesterday. Despite Revlimid’s delay, the firm believes Celgene’s other clinical programs have stayed on track. The company’s management’s reiteration of its 2012 guidance and its decision to give a 2015 guidance range for the first time has encouraged William Blair.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.